NeuroPace (NPCE) Cash from Investing Activities Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 0.00% |
| 10 | NeuroPace | 462.46 Mn | 410.76 Mn | 18.91 Mn | 25.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.60% |
| Mar 31, 2026 | -216.22% |
| Dec 31, 2025 | -104.95% |
| Sep 30, 2025 | -102.14% |
| Jun 30, 2025 | -105.19% |
| Mar 31, 2025 | -101.54% |
| Dec 31, 2024 | -43.45% |
| Sep 30, 2024 | -66.60% |
| Jun 30, 2024 | -38.92% |
| Mar 31, 2024 | -76.20% |
| Dec 31, 2023 | -61.02% |
| Sep 30, 2023 | -39.86% |
| Jun 30, 2023 | -35.65% |
| Mar 31, 2023 | 3,390.20% |
| Dec 31, 2022 | 5,877.92% |
| Sep 30, 2022 | 3,767.89% |
| Jun 30, 2022 | 110.29% |
| Mar 31, 2022 | 93.92% |
| Dec 31, 2021 | 98.47% |
| Sep 30, 2021 | 24.00% |